APVO - צמיחת מכירות משנה לשנה (TTM) aptevotherapeutics.com

Aptevo Therapeutics (APVO) develops innovative antibodies to combat cancer, leveraging the ADAPT platform and strategic partnerships to minimize costs. This 12-month YoY sales change chart demonstrates revenue resilience, with the current value standing at 0.00. However, geopolitical tensions are complicating logistics and clinical trials. Outlooks remain positive as demand for immuno-oncology grows alongside the clinic network.
Aptevo - פילוחים אנליטיים ומדדי מפתח (APVO)

This indicator measures the percentage change in aggregate revenue over the last 12 months relative to the same period last year, neutralizing short-term volatility and inflationary distortions. For Aptevo Therapeutics (APVO), the 12-month year-over-year revenue growth rate reflects the monetization efficiency of its bispecific antibody developments, allowing investors to assess the sustainability of operating income amid a dependence on external investment capital.